What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care
- Psychiatrists’ Changing Perceptions of Psychedelics
- Ketamine’s Role in Opening the Door; At-Home Ketamine
- The Dual Mechanism of Psychedelics
- Do We Need the Trip?
- Compass’ Phase 3 and Partial Response
- Sacling Psychedelics: Reimbursement, RVUs, and Real-World Delivery
- Setting Up a Psychedelic Research Programme
Dr. Brian Barnett is a staff psychiatrist at Cleveland Clinic’s Center for Behavioral Health and the Clinical Director of the Cleveland Clinic Psychiatric Treatment-Resistance Program. He has served as principal investigator on clinical trials investigating ketamine, LSD, psilocybin and other psychedelics.
He sat down with Psychedelic Alpha’s Josh Hardman in New Orleans to discuss psychiatrists’ perceptions of the field, the role of ketamine in ‘kicking the door down’ for psychedelics, whether the subjective effects are necessary for therapeutic outcomes, Compass Pathways’ Phase 3 readout, how psychedelic treatments can scale, if approved, and advice for researchers.
This is a lengthy interview, so we have used subheadings to aid navigation…
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks